Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20556326 | 1.00 | MEN1 (0.42) | MEN1KMT2AMALT1ALDH1A1LMNA | |
| SCHEMBL28720025 | 0.91 | MEN1 (0.45) | MEN1KMT2AMALT1ALDH1A1NPSR1 | |
| SCHEMBL28720126 | 0.91 | MEN1 (0.45) | MEN1KMT2AMALT1ALDH1A1NPSR1 | |
| SCHEMBL10328418 | 0.90 | MEN1 (0.43) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL25352999 | 0.83 | MMP9 (0.43) | — | |
| SCHEMBL30299124 | 0.83 | MMP9 (0.43) | ALDH1A1LMNA | |
| SCHEMBL30299079 | 0.83 | MMP9 (0.43) | — | |
| SCHEMBL14476195 | 0.81 | MEN1 (0.52) | MEN1KMT2AMALT1ALDH1A1LMNA | |
| SCHEMBL20556383 | 0.81 | CA1 (0.45) | MALT1ALDH1A1LMNAPKMF2 | |
| SCHEMBL20556384 | 0.81 | CA1 (0.45) | MALT1ALDH1A1LMNAPKMF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | WUXI APPTEC CO., LTD (CN) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327367-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MEN1 2531/4885KMT2A 3283/4885MALT1 3363/4885 |
| US-20230133817-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MEN1 2531/4885KMT2A 3283/4885MALT1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.